In Interim Results ts 2016 - September 2016 Midatech Pharma plc - - PowerPoint PPT Presentation

in interim results ts 2016 september 2016
SMART_READER_LITE
LIVE PREVIEW

In Interim Results ts 2016 - September 2016 Midatech Pharma plc - - PowerPoint PPT Presentation

In Interim Results ts 2016 - September 2016 Midatech Pharma plc Disclaimer THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR


slide-1
SLIDE 1

In Interim Results ts 2016 - September 2016

Midatech Pharma plc

slide-2
SLIDE 2

Disclaimer

THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. IN PARTICULAR, THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract commitment or investment decision in relation thereto. The information contained in this presentation has been prepared by Midatech Pharma plc ("Midatech" or the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment. This presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and therefore it is being delivered for information purposes only to a very limited number of persons and companies who are persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or are high net worth companies within the meaning set out in Article 49 of the Order or are otherwise permitted to receive it. Any other person who receives this presentation should not rely or act upon it. By accepting this presentation and not immediately returning it, the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive the presentation. This presentation is not to be disclosed to any other person or used for any other purpose. Please note that the information in this presentation has yet to be announced or otherwise made public and as such constitutes relevant information for the purposes of section 118 of FSMA and non-public price sensitive information for the purposes of the Criminal Justice Act 1993. You should not therefore deal in any way in the securities of the Company until after the formal release of an announcement by the Company as to do so may result in civil and/or criminal liability. Panmure Gordon (UK) Limited ("Panmure Gordon") is acting in the provision of corporate finance business to the Company, within the meaning of the Financial Conduct Authority’s Conduct of Business Sourcebook (“COBS”), and no-one else in connection with the proposals contained in this Presentation. Accordingly, recipients should note that Panmure Gordon is neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Panmure Gordon under the COBS nor for providing advice in relation to the proposals contained in this presentation. While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as “Information”) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this presentation. In particular, unless expressly stated otherwise, the financial information contained in this presentation relates to the Company and its subsidiary undertakings. To the extent available, the industry and market data contained in this presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this presentation come from the Company’s internal research and estimates based on the knowledge and experience of the Company’s management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this presentation. Neither the issue of this presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective

  • investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this presentation, the Company does not undertake or agree to any obligation

to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation which may become apparent. This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. In particular, this presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Each party to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters. This presentation and the information contained herein are not an offer of securities for sale and are not for publication and or distribution in the United States or to any US person (within the meaning of Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”)) or in Canada, Australia, South Africa or Japan or any jurisdiction where such offer or distribution is unlawful. Any failure to comply with this restriction may constitute a violation of United States securities laws. The securities of the Company have not been registered under the Securities Act and may not be offered or sold in the United States or to any US person unless the securities are registered under the Securities Act or an exemption therefrom is available. Certain statements in this presentation may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “potential,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results, the acquisition, levels of activity, performance, or achievements. Any forward-looking statements are based on currently available competitive, financial and economic data together with management’s views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and

  • uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Reference

should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies (“AIM Rules”), the Disclosure and Transparency Rules (“DTRs”) and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking

  • statements. These forward-looking statements speak only as of the date of this presentation. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except

as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events

  • r otherwise arising.

2

slide-3
SLIDE 3

A Rapidly Growing International Specialty Pharmaceutical Company

UK-based public company (plc)

  • c.100 employees across Europe & the US
  • Diversified strategy and sources of revenue with innovative R&D pipeline
  • Highly experienced pharma management team

Established US Commercial Presence (40 team members)

  • Six marketed products: potential aggregate peak sales of $50 million
  • Double-digit top-line growth expected over the next 12 months
  • Expect lead product Q-Octreotide to be filed for marketing authorisation by end 2017/beginning of 2018

Fully integrated R&D capabilities with two platform technologies

  • Glycan coated gold nanoparticles (GNP)
  • CAD “printed” sustained-release particles (Q-Sphera)
  • Drives a novel, lower risk development pipeline based on known therapeutic agents

Organisation Commercial Force R&D

3

slide-4
SLIDE 4

2016 H1 Operational Highlights

  • Successful integration and good sales performance

from our newly acquired US commercial business

  • Six months to June $4.58m (£3.19m), growth of 104% vs. H1

2015 ($2.24m)*

  • Launch of our anti-nausea product Zuplenz in the US
  • Approved for use in multiple indications in a $10bn US market
  • Bolsters marketed oncology product portfolio and leverages
  • US commercial infrastructure
  • Preparation for final development &

commercialisation of Q-Octreotide

  • Manufacturing scale up started in H1 – investment in our

Bilbao facility

  • Good in vivo data achieved
  • Planned bioequivalence study to start H1 2017 and filing for

first marketing authorisations anticipated by 2018

 Prior to its acquisition by Midatech, DARA Biosciences, Inc. had revenue from product sales of $2.24m in the six months to 30 June 2015

  • Product candidate testing in-vivo for glioblastoma

(GBM) and hepatocellular carcinoma (HCC)

  • Dana Farber testing Midatech’s targeted nanomedicines

against glioblastoma

  • GBM and HCC programmes on track for product selection

by the end of 2016

  • Dosing due to commence in Q3 2016 in first

immunotherapy Phase I study for type I diabetes

  • Further positive progress seen in the period in the

Company’s OpsiSporin and MTX110/111 (DIPG) programmes

In 2016, Midatech Pharma continues to execute against all key areas of its business model

4

slide-5
SLIDE 5

DIPG (MTX110) named patient basis Ferralet Aquoral Soltamox Gelclair Oravig Zuplenz

Since IPO, Midatech’s R&D portfolio has grown significantly and a US-marketed portfolio has been established

Early-stage portfolio at IPO Progress into a well-balanced portfolio with revenues and pipeline

Brain

Oncology Endocrinology Ophthalmology, Neurology & Others

Ovary Liver Pancreas Q-Cancer Beads GLP1 / Q-Exenatide Combo Q-Octreotide Eye Disease Programmes Blood Brain Barrier Programme Psoriasis Research Collaboration Peptide Research Collaboration Research Pre-C

  • Ph. I

Insulin

IPO proceeds and listing facilitated a portfolio step-change

Oncology

Research Pre-C

  • Ph. I
  • Ph. II
  • Ph. III

Sub. Marketed Q-Octreotide (MTD201) Glioblastoma (MTR103) Liver Hepatocellular Carcinoma (MTR104) Squamous Cell Carcinoma (MTR105) GNP TAM Programme GNP Dendritic Vaccine Programme

CNS / Ophthalmology

OpsiSpirin (MTD202)

Partnered Programmes

Ophthotech 1 Ophthotech 2 EU Biotech A – Ophtha Programme Type 1 diabetes vaccine MTX102 FP7 EU

5

IPO funds provided:

  • Significant uplift in

R&D productivity

  • Facilitated on-market

product acquisitions

  • Enabled

commercialisation

Marketed in the US

CED/DIPG (MTX111)

slide-6
SLIDE 6

6

Products & commercial platform

slide-7
SLIDE 7

Midatech Pharma US (MTPUS): Fully Integrated Commercial Platform

MTPUS Commercial Operations

  • MTPUS has an effective commercial platform to sell and market our

current oncology supportive care portfolio (6 products)

  • 25 representatives in the highest prescribing oncology markets
  • Year-on-year sales up 104% to $4.5 million
  • Established through acquisition of DARA BioSciences, Inc. for $24 million

the complementary product Zuplenz for $3.75 million*

  • Creates potential peak sales opportunity of $50 million
  • Internal development pipeline will help to achieve scale
  • Long-term cash flows to fund on-going biotechnology programmes

 Initial consideration subject to certain adjustments and additional, conditional payments

7

slide-8
SLIDE 8

Zuplenz

  • Post-chemo radiotherapy anti-nausea and vomiting product
  • Acquired for $3.75m (plus back-end milestones based on

excess over forecast sales)

  • Expected pay-back time <18 months
  • Entrant into $10bn / 20m Prescription per annum US 5HT3 Market
  • 0.25% Market Share would give sales of $25m/pa
  • 0.5% Market Share would give sales of $50m/pa
  • Coverage by 11/13 Commercial Insurers (>250m Population)
  • Competitive Pricing $500/Pack (range of competition $250-$1,800)
  • Superior support and presentation
  • Zero patient co-pay program
  • May be taken with or without water and dissolves in seconds
  • No stickiness from a patch or gritty sensation from a tablet

8

slide-9
SLIDE 9

Gelclair

  • Acquired via Dara BioSciences acquisition
  • Indicated for Oral Mucositis

(caused by chemotherapy or radio therapy)

  • Lead product in uncompetitive environment

(compounded magic mouthwash)

  • Coverage by 11/13 Commercial Insurers (>250m Population)
  • Superior support and mechanism of action vs. magic mouthwash
  • Zero patient co-pay program
  • 3rd year of sales in 2016
  • Sales history 2014-5 :
  • 2014 – Gross $2.1m / Net $1.7m
  • 2015 – Gross $4.5m / Net $3.3m
  • Estimated peak annual sales potential c$10m

9

slide-10
SLIDE 10

Oravig

  • Buccal Tablet for treatment of Oral “Thrush” associated with

Radio/ Chemo and in HIV patients

  • Launched in October 2015
  • Coverage by 11/13 Commercial Insurers (>250m Population)
  • Over 4m rx written annually for localised treatment
  • 0.1% market share = $3m annual sales (targeting 0.3%-0.5%

market share)

  • Superior support and presentation
  • Zero patient co-pay program
  • Once-daily, local treatment
  • Does not interrupt eating or drinking
  • Annual sales potential c$10m

10

slide-11
SLIDE 11

Research & development

slide-12
SLIDE 12

Development Pipeline: 10 Programs

12 RESEARCH PRECLINICAL PHASE I PHASE II

Immunotherapy Cancer

OpsiSporin Uveitis MTD202

CNS/Ocular

Q-Octreotide Carcinoid MTD201 Glioblastoma MTR103 DIPG Pontine Glioma MTX110 named patient basis Liver Hepatocellular Carcinoma MTR104 Immuno-Oncology Vaccine MTR

Immuno-Oncology TAM MTR

PHASE III

Squamous Cell Carcinoma MTR105 Type 1 Diabetes Vaccine MTX102

Development of multiple, high-value, targeted therapies for major diseases with unmet medical need

CED/DIPG MTX111

slide-13
SLIDE 13

Key Partnerships Pipeline

13 RESEARCH PRECLINICAL PHASE I PHASE II

Immunotherapy CNS/Ocular

  • Partnered development programmes for high-value, targeted therapies for further indications
  • Partnerships and collaborations with specialty and major pharmaceutical companies and universities
  • Already revenue generating

Ophthotech 1 Ophthotech 2 EU Biotech A – Ophtha Programm Type 1 Diabetes Vaccine MTX102 FP7 EU

slide-14
SLIDE 14

Sustained Release Microsphere Technology

slide-15
SLIDE 15

Q-Octreotide (MTD201)

15

Positive pre-clinical data

  • Compares favourably with Sandostatin LAR
  • Pharmacokinetic data correlates well with PD effects
  • Injections well tolerated with no site reaction

Steps to commercialisation

  • Pilot human pharmacokinetic study planned Q1 2017,

followed by bioequivalence or therapeutic equivalence programme in H1 2017

  • Marketing authorisation submission anticipated in the

period Q4/17 - Q4/18

Currently in final stages pre-clinical development

  • Formulation complete
  • Entering bio-equivalence or therapeutic equivalence studies end 2016/7
  • Planned US launch in 2018/9

Manufactured in house with terminal sterilisation

  • Saves time c6 months from CMO
  • Investing now in preparation of full commercialisation
  • Enable other projects using Q-Sphera technology (e.g.

Ophthotech), to capture more value

Peak market potential c.$100m pa

  • Own sales targeted in the USA
  • Centurion out-licence achieved for Turkish rights

Advantages

  • Significantly easier to reconstitute and administer

than current Sandostatin product

  • Seconds to reconstitute vs 35 minutes
  • In home administration with patient friendly device
  • vs. current administration in clinic via IV
  • Smaller needle
  • Can reduce clinical visit time by more than half

Long-acting formulation of Octreotide acetate for chronic treatment of carcinoid (cancer) & acromegaly Market worth over $2bn (Sandostatin LAR $1.6bn)

01 02 03 04 05

slide-16
SLIDE 16

Opsisporin (MTD202)

16

Development pathway

  • IND enabling to commence Q4 2016
  • toxicology program will complete approx. Q4 2017
  • Phase I Q4 2017/Q1 2018

Successful PoC completed in several animal models

  • Clear dose response established in prophylactic model
  • Efficacy to be established in therapeutic model
  • Terminal sterilisation study underway

Intravitreal injection via 27-30G needle directly to vitreous and posterior eye, with minimal transfer to the blood Orphan Indication. Designation application to be submitted September 2016

Advantages

  • Product will be steroid and

immunosuppressant sparing

  • Delivered intravitreal at 1000 fold lower

doses than oral cyclosporine

  • Currently no approved intravitreal

cyclosporine or other immunosuppressant treatment option available OpsiSporin is injectable sustained release formulation

  • f cyclosporine for treatment of non-infective uveitis

Uveitis growing rapidly ~$1.3bn market, current treated by eyedrops, immuno-suppressives or systemic

01 02 03 04 05

slide-17
SLIDE 17

GNP Oncology Nanotechnology

slide-18
SLIDE 18

Glioblastoma (GBM) (MTR103)

18

Combined targeting and therapeutic

  • Development in conjunction with Dana Farber institute
  • Candidate selection planned Q3 2016
  • IND enabling to commence by end of 2016
  • Filing for marketing authorisation anticipated by 2018

Survival typically 12 to 15 months

  • Less than 5% surviving greater than five years

Orphan Indication – designation application to be submitted

  • GNP’s targeted to bind tumour

specific receptors on GBM cells; internalised GNPs developed to release therapeutic payload intracellularly

  • GNP design customised to maximise

uptake for specific GBM indication Worldwide estimated 240,000 cases of brain and nervous system tumours per year

  • GBM is most common, and most lethal, of these tumours

Systemic and intra-tumoural administration

01 02 03 04 05

slide-19
SLIDE 19

Liver Hepatocellular Carcinoma (HCC) (MTR104)

19

Combined targeting and therapeutic

  • Candidate selection planned H2 2016
  • IND enabling to commence Q4 2016, Q1 2017

Surgical resection major treatment option

  • But only 10 – 20% can be removed completely

Current chemotherapeutic options too toxic

  • Opportunity to reduce through targeting
  • Target receptors on HCC tumour

cells GPC3 to bind and internalise GNPs where the therapeutic payload would be released Sixth most frequent cancer globally and the second leading cause of cancer death Orphan Indication – designation application to be submitted

01 02 03 04 05

slide-20
SLIDE 20

DIPG: Diffuse Interstitial Pontine Glioma (MTX110)

20

Midatech actively pursuing local delivery directly into the tumour through Convection Enhanced Delivery (CED) that delivers therapeutic constructs via a series of catheters fixed into the substance of the tumours Ultra-high unmet need, potential orphan indication Compassionate use/named patient program: MTX110

  • UK: the first UK patient continues to be infused

monthly (6 infusions to date)

  • US: a single patient received their first dose In August

MTX 111

  • Other DIPG constructs in R&D:

Maytansinoids (AT), Doxorubicin (TPI2), Cilengitide (RGD), Irinotecan (TPI1), Aurostatins (AT; vedotins), HDACi’s

Ultra rare childhood brain tumour

  • c1,000 cases / year worldwide
  • Average survival, 7 months; universally fatal

Research & Development next steps:

  • Regulatory interactions through 2016 – high level of support for

program by regulatory agencies

  • Evaluating clinical trial with ultimately selected construct

01 02 03 04 05

slide-21
SLIDE 21

GNP Immunotherapy

slide-22
SLIDE 22

GNP ASI Immunotherapy vaccine (MTX102)

22

  • Combination of Midatech GNP technology and

Antigen Specific Immunotherapy (ASI)

  • 20% of population suffer from autoimmune disease
  • Current autoimmune treatments suppress whole immune

system which increases risk of infection and cancer

  • GNP ASI stimulates a disease-regulating response without

affecting the rest of the immune system

  • Initial focus is largest autoimmune disease, diabetes,

however the programme also has broad potential applicability in oncology

  • Positive pre-clinical data
  • GNP ASI substantially enhances disease-regulating response
  • Preferentially targets specific immune cells
  • Clinical and commercial production
  • Manufactured in-house with fill and finish by CMO
  • DEVELOPMENT
  • Phase I study start Q3 2016, complete Q4 2016
  • Regulatory approvals for studies obtained in UK and

Sweden

slide-23
SLIDE 23

Immunotherapy ‘Pipeline’

Antigen Specific Immunotherapy (ASI):

  • GNP ASI data suggests enhanced tolerogenic response in autoimmune disease

Dendritic or Peptide Vaccine

  • GNP peptide conjugates enhance proliferation of cytotoxic antigen-specific CD8+ T cells

Tumour Associated Macrophages

  • GNP conjugates activate M2 macrophages towards a classical M1 cancer killing phenotype

23

slide-24
SLIDE 24

Financials

slide-25
SLIDE 25

2016 H1 Financial Highlights

  • Total revenue grew from £0.32 million in H1 2015 to £3.80 million (up 1,088%)
  • Research and development costs of £2.05 million, a 13% increase from £1.82 million in H1 2015
  • Administrative expenses increased from £3.77 million in H1 2015 to £6.82 million (up 81%), primarily due

to the Company’s enlarged commercial infrastructure from the acquisition of Midatech Pharma US

  • Net cash outflow used in operations (after changes in working capital) was £8.25 million, up 55% from

£5.31 million in H1 2015. The cash balance at 30 June 2016 was £7.23 million

  • Loss per share increased by 39% to 25p (H1 2015: 18p)

25

slide-26
SLIDE 26

26

Consolidated Income Statement

Six months ended 30 June 2016 Six months Ended 30 June 2015

£'000 £'000 Revenue 3,456 121 Grant revenue 347 203 _______ _______ Total revenue 3,803 324 Cost of sales (1,032)

  • _______

_______ Gross profit 2,771 324 Research and development costs (2,048) (1,822) Distribution costs, sales and marketing (4,237)

  • Administrative costs

(6,821) (3,768) _______ _______ Loss from operations (10,335) (5,266) Finance income 765 28 Finance expense

  • (12)

_______ ________ Loss before tax (9,570) (5,250) Taxation 1,365 356 _______ ________ Loss after tax attributable to the owners of the parent (8,205) (4,894) ________ ________ Loss per share Basic and diluted loss per ordinary share – pence (25p) (18p)

slide-27
SLIDE 27

As at 30 June 2016 As at 31 Dec 2015 £’000 £’000

Non-current assets Property, plant and equipment 2,469 1,984 Intangible assets 42,510 41,339 Other receivables due in greater than one year 387 425

_______ _______

45,366 43,710

_______ _______

Current assets Inventories 787 459 Trade and other receivables 1,503 2,496 Taxation 1,723 1,201 Cash and cash equivalents 7,226 16,175

_______ _______

11,239 20,331

_______ _______

Total assets 56,605 64,041

_______ _______

Non-current liabilities Borrowings 1,440 1,508 Deferred tax liability 6,520 6,547

_______ _______

7,960 8,055

_______ _______

Current liabilities Trade and other payables 5,790 7,084 Borrowings 360 442 Derivative financial liability – equity settled 965 1,573 Provisions 799

  • _______

_______

7,914 9,099

_______ _______

Total liabilities 15,874 17,154

_______ _______

27

Consolidated Balance Sheet

slide-28
SLIDE 28

28

Consolidated Cash Flow Statement

Six months ended 30 June 2016 Six months Ended 30 June 2015 £’000 £’000

Cash used in operations (8,248) (5,307) Taxes received 204

  • _______

_______ Net cash used in operating activities (8,044) (5,307) _______ _______ Investing activities Purchases of property, plant and equipment (753) (733) Interest received 158

  • _______

_______ Net cash used in investing activities (595) (733) Financing activities Payments to finance lease creditors (15) (11) Repayment of borrowings (149) (34) Issue of borrowings

  • 102

Share issues net of costs

  • 1

_______ _______ Net cash (used in)/generated from financing activities (164) 58 Net (decrease)/increase in cash and cash equivalents (8,803) (5,982) Cash and cash equivalents at beginning of year 16,175 30,325 Exchange gains on cash and cash equivalents (146)

  • _______

_______ Cash and cash equivalents at end of year 7,226 24,343 _______ _______

slide-29
SLIDE 29

2016 and H1 2017 Expected News Flow

29

  • Gelclair: Maintenance of growth and leadership

position in US market

  • Oravig: First full year of sales in US post launch in

Q4 2015

  • Zuplenz: First full year of sales in US post launch

in Q2 2016

  • Q-Octreotide human bio-equivalence studies to

commence in H1 2017

  • Further preclinical data across multiple

programmes

  • Further updates on brain tumour cancer therapy

programme (DIPG) for initial compassionate use patients in H2 2016

  • First immunotherapy vaccine to commence

dosing in clinical trials in Q3 2016

  • Further deployment of core technologies via

licensing deals to new and existing partners

  • Completion of expansion of Bilbao

manufacturing facility for scale-up of sustained release technology in late 2016

slide-30
SLIDE 30

Summary

30

Leading proprietary platform technologies

  • Gold nanoparticles
  • Sustained-release delivery
  • Targeted delivery and release of existing therapeutics to the “right place” at the “right time”
  • Focused on development and commercialisation of multiple high-value, targeted therapies for major

diseases with unmet medical needs

  • US commercial arm has six products in oncology treatment and supportive care, driving revenue

growth

  • Own product launches from 2018-19 at high margin

Midatech Pharma an international specialty pharma company

  • Continue to invest in products and technology to drive value for stakeholders in the business
  • Developing novel pre-clinical and clinical portfolio pipeline
  • Seeking attractive acquisition targets, products and technology

On-track for execution of three-pronged strategy for growth and value creation

Photograph of section through needle showing microspheres Representation of a gold nanoparticle